CompletedNot Applicable

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Austria, Germany315 participantsStarted 2012-07

Plain-language summary

This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment regimen.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The patient has not received Vimpat® more than 7 days prior to start of Non-Interventional Study (NIS) * The patient must have a diagnosis of epilepsy with partial-onset seizures with or without secondary generalization * Based on the physician's clinical judgment, it is in the patient's best interest to be prescribed adjunctive Vimpat® (ie, the decision to prescribe Vimpat® is made by the physician) * Patient must be at least 18 years of age * The patient must have had at least one seizure within the last 3 months prior to enrolment

What they're measuring

The Percent Change in Ratio of Dose and Defined Daily Dose (DDD) for the Drug Load of Concomitant Anti-Epileptic Drugs (AEDs) From Baseline to the End of Observation Period (Day 0 to 6 Months)

Timeframe: From Baseline (Day 0) to 6 months

Trial details

NCT IDNCT01673282

SponsorUCB Pharma GmbH

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-07

Results submitted2016-06-29

View on ClinicalTrials.gov More Focal Epilepsy With and Without Secondary Generalization trials